VNDA

HETLIOZ® (tasimelteon)

Non-24-Hour Sleep-Wake Disorder (Non-24)

Stage (next event)

Expected Date

Quarterly Sales (Approved)

January 2021

Catalyst Info & Data Links

TITLE: HETLIOZ® (tasimelteon) - Quarterly Sales

WHAT IS THE CATALYST EVENT?

  • Quarterly sales


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • January 2021 (Est)


PRIOR DATA/EVENTS

PRESS RELEASE

Mechanism of Action

MECHANISM OF ACTION / RATIONALE

  • The precise mechanism by which tasimelteon exerts its therapeutic effect in patients with Non- 24 is not known. Tasimelteon is an agonist at melatonin MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms (Learn more pg.6)

COMPETITORS

  • HETLIOZ® (tasimelteon) - The first and only FDA-approved treatment for Non-24-Hour Sleep-Wake Disorder (Non-24).

Updated by HC

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon